leadf
logo-loader
viewValiRx PLC

ValiRx PLC gets go-ahead to expand and accelerate early-stage cancer study

George Morris, chief operations officer at ValiRx Plc (LON:VAL) tells Proactive the've been given the go-ahead by regulators to expand and accelerate their early-stage cancer study.

The Medicines and Healthcare Regulator Agency and Research Ethics Committee are allowing them to substantially raise the dosing of VAL201, a treatment for metastatic prostate cancer and other solid tumours.

They'll be doing this to find the correct therapeutic levels of treatment to administer in order to try to stop the disease’s spread.

Quick facts: ValiRx PLC

Price: 21 GBX

AIM:VAL
Market: AIM
Market Cap: £13.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Golden Rim Resources kicks off 15,000 metre auger drilling program at Kada...

Golden Rim Resources Ltd's (ASX:GMR) Craig Mackay caught up with Proactive's Andrew Scott soon after announcing they've started an extensive fieldwork program comprising 15,000 metres of power auger drilling utilising two rigs at the Kada gold project in Guinea. It will primarily focus on a...

29 minutes ago

2 min read